A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 33,697 shares of CPRX stock, worth $765,258. This represents 0.01% of its overall portfolio holdings.

Number of Shares
33,697
Previous 35,188 4.24%
Holding current value
$765,258
Previous $560,000 6.96%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$14.68 - $16.92 $21,887 - $25,227
-1,491 Reduced 4.24%
33,697 $521,000
Q1 2024

May 15, 2024

SELL
$13.18 - $17.11 $30,498 - $39,592
-2,314 Reduced 6.17%
35,188 $560,000
Q4 2023

Feb 14, 2024

SELL
$11.78 - $17.29 $901,217 - $1.32 Million
-76,504 Reduced 67.11%
37,502 $630,000
Q3 2023

Nov 14, 2023

BUY
$11.69 - $15.02 $41,289 - $53,050
3,532 Added 3.2%
114,006 $1.33 Million
Q2 2023

Aug 14, 2023

SELL
$11.5 - $18.08 $333,235 - $523,904
-28,977 Reduced 20.78%
110,474 $1.48 Million
Q1 2023

May 15, 2023

BUY
$14.34 - $21.05 $1.73 Million - $2.53 Million
120,406 Added 632.22%
139,451 $2.31 Million
Q4 2022

Feb 14, 2023

SELL
$12.25 - $19.5 $381,342 - $607,035
-31,130 Reduced 62.04%
19,045 $354,000
Q3 2022

Nov 14, 2022

BUY
$7.06 - $15.52 $354,235 - $778,716
50,175 New
50,175 $644,000
Q4 2020

Feb 16, 2021

SELL
$2.97 - $3.83 $96,979 - $125,060
-32,653 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$2.97 - $5.08 $110,540 - $189,072
-37,219 Reduced 53.27%
32,653 $97,000
Q2 2020

Aug 13, 2020

SELL
$3.48 - $5.05 $198,575 - $288,163
-57,062 Reduced 44.95%
69,872 $323,000
Q1 2020

May 15, 2020

BUY
$2.61 - $5.21 $235,996 - $471,088
90,420 Added 247.63%
126,934 $489,000
Q4 2019

Feb 14, 2020

SELL
$3.67 - $5.7 $12,133 - $18,844
-3,306 Reduced 8.3%
36,514 $137,000
Q3 2019

Nov 14, 2019

BUY
$3.89 - $7.43 $154,899 - $295,862
39,820 New
39,820 $211,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.34B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.